Vitiligo is a complex disease whose pathogenesis results from the interaction of genetic
components, metabolic factors linked to cellular oxidative stress, melanocyte adhesion to the …

Despite historical mischaracterization as a cosmetic condition, patients with the autoimmune
disorder vitiligo experience substantial quality‐of‐life (QoL) burden. This systematic …

Background Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A
cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in …

Background Vitiligo, an autoimmune disorder characterised by skin depigmentation, is
associated with reduced quality of life (QoL). Vitiligo may be under‐reported, in part because …

Abstract The Food and Drug Administration (FDA) has authorized Ruxolitinib (Opzelura), as
first at-home treatment for non-segmental vitiligo, an autoimmune condition that causes …

Vitiligo is an autoimmune skin disease characterized by the destruction of melanocytes by
autoreactive CD8+ T cells. Melanocyte destruction in active vitiligo is mediated by CD8+ T …

Vitiligo, a common depigmenting cutaneous condition, is thought to affect 0.5%-2% of the
world's population. During this condition, melanocytes are selectively lost, resulting in non …

Epidermal melanocyte loss in vitiligo, triggered by stresses ranging from trauma to emotional
stress, chemical exposure or metabolite imbalance, to the unknown, can stimulate oxidative …

Vitiligo is a common acquired depigmenting disease characterized by the loss of functional
melanocytes and epidermal melanin. Vitiligo has a long treatment cycle and slow results …

Vitiligo is a chronic treatment‐resistant autoimmune disorder characterized by circumscribed
depigmented maculae. This study was conducted to evaluate the efficacy and safety of …